STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.
Hepatitis C patients are encouraged to take part in a global patient survey - HCV Quest – in order to better understand the impact of the disease on patients around the world. Hurry – survey closes on 30th November 2014.
Gilead Sciences BOSON trial - the Clinical Research Network's 'Spotlight on hepatitis research' highlights the importance of the academic-industrial collaboration within STOP-HCV.
STOP-HCV award now active
The official start date for STOP-HCV was 16th September 2013. Work has now begun to meet the consortiums aims.